No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

byKathleen Lau

March 18, 2021

in StudyGraphics

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

RelatedReports

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Weekly Rewinds

2 Minute Medicine Rewind

January 13, 2026

Testosterone replacement in male cancer survivors helps improve body composition

Oncology

New model enhances prediction of prostate cancer-specific mortality

January 12, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]

January 12, 2026

Chronic Disease

High-flow nasal therapy with room air and fan therapy provide modest relief of dyspnea in advanced cancer patients who are not hypoxemic

January 12, 2026

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

Parents often unaware of adolescents’ suicidal thoughts

Ketamine infusion significantly reduces depressive symptoms among adolescents with treatment-resistant depression

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

RELATED REPORTS

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

RelatedReports

Recent Reports